Satsuma Pharmaceuticals Inc

NASDAQ:STSA  
0.88
-0.04 (-4.33%)
7:43:50 PM EDT: $0.93 +0.05 (+5.12%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Satsuma Pharmaceuticals Inc Stock, NASDAQ:STSA

400 Oyster Point Boulevard, Suite 221, San Francisco, California 94080
United States of America
Phone: +1.650.410.3200
Number of Employees: 21

Description

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.